Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented City Therapeutics in the transaction. City Therapeutics, a biopharmaceutical company, announced raising $135 million in Series A financing...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Xaira Therapeutics in the transaction. Xaira Therapeutics (Xaira), an AI biotechnology company, from formation and through $1 billion...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented ARCH Venture Partners on the deal. ARCH Venture Partners led the $270 million Series A financing of Orbital Therapeutics, a company focused on enhancing...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Viridos on the deal. Viridos, the leading algae biofuel company, announced its $25 million Series A financing led by Breakthrough Energy Ventures (BEV) and...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Brightseed on the deal. Brightseed, a San Francisco-based developer of plant nutrient technology, announced its $68 million Series B financing led by Temasek. Brightseed...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Xencor on the deal. Xencor, a clinical-stage biopharmaceutical company, announced its $100 million collaboration agreement with Johnson &...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Amgen Inc on the deal. Amgen Inc (NASDAQ:AMGN) announced its acquisition of Rodeo Therapeutics. Amgen is one of...
You must be a Standard 1 Year member to access this content.
